News RRMS Treatment from Antisense Highly Effective in Clinical Trials RRMS Treatment from Antisense Highly Effective in Clinical Trials by Maureen Newman | September 23, 2014 Share this article: Share article via email Copy article link For the first time, an antisense oligonucleotide has been shown to be effective in treating relapse-remitting multiple sclerosis. A phase 2a clinical trial of Antisense Therapeutics Limited’s ATL1102, a CD49d antisense drug, showed that the treatment quickly reduced brain lesions in RRMS patients following the start of therapy. As a result, if trials continue and ATL1102 is brought to market, a new, highly effective treatment will be available that lacks the limitations of some current treatments. “There are a number of unresolved issues with current multiple sclerosis drugs including the occurrence of neutralising antibodies to the antibody, protein, and peptide multiple sclerosis drugs as well as long-time safety concerns with the more recently approved drugs,” said Volker Limmroth, MD, PhD, of the University of Cologne, who was lead author of the study published in Neurology, in a news release. “There is a clear need for more effective and safe drugs for the significant population of multiple sclerosis patients who have relapses and non-stable disease.” Dr. Limmroth, along with colleagues, published the results of the phase 2a trial under the title, “CD49d Antisense Drug ATL1102 Reduces Disease Activity in Patients with Relapse-Remitting MS.” A total of 77 patients were enrolled in the study, and all had relapsing-remitting multiple sclerosis. After only two months of dosing, ATL1102-treated patients showed a significantly lower cumulative number of new active brain lesions compared to placebo-treated patients. [adrotate group=”4″] Interestingly, the therapy was deemed to be as good as, or superior to, the popular multiple sclerosis drug Tysabri. Antisense Therapeutics estimates that ATL1102 could be a potentially safer, cheaper, and more convenient alternative to Tysabri therapy. Print This Page About the Author Maureen Newman Maureen Newman is a science columnist for BioNews Texas. She is currently a PhD student studying biomedical engineering at University of Rochester, working towards a career of research in biomaterials for drug delivery and regenerative medicine. She is an integral part of Dr. Danielle Benoit's laboratory, where she is investigating bone-homing therapeutics for osteoporosis treatment. Tags RRMS
April 26, 2024 News by Margarida Maia, PhD Employment, income drop steadily over 2 decades after onset of MS
April 26, 2024 News by Marisa Wexler, MS Machine learning model predicts CIS to MS conversion risk: Study
April 25, 2024 Columns by Benjamin Hofmeister Finding safety while living with the constant threat of MS progression